Parnax Lab's Q4 FY 2025-26 Quarterly Results

Result Summary

• Parnax Lab Ltd reported a 12.1% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 44.8%.
• Its expenses for the quarter were up by 14.9% QoQ and 50.2% YoY.
• The net profit decreased 19.2% QoQ and decreased 25.3% YoY.
• The earnings per share (EPS) of Parnax Lab Ltd stood at 1.9 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Parnax Lab Ltd is a company that operates within the pharmaceutical industry. It primarily focuses on the manufacturing and distribution of pharmaceutical products, which include active pharmaceutical ingredients (APIs), finished dosage forms, and other specialized pharmaceutical solutions. The company is known for its commitment to quality and innovation in the pharmaceutical sector. Key recent developments or major strategic initiatives by the company are not available from the provided data.

Revenue

The revenue garnered by Parnax Lab Ltd in the fourth quarter of the fiscal year 2026 (Q4FY26) reached ₹71.62 crores, showing a notable increase from the previous quarter (Q3FY26) which was ₹63.91 crores. This marks a quarter-over-quarter (QoQ) growth of 12.1%. Compared to the same quarter in the previous fiscal year (Q4FY25), where the revenue was ₹49.46 crores, there is a year-over-year (YoY) growth of 44.8%. This growth in total income indicates that the company has seen significant upward movement in its revenue generation over both the quarter and year.

Profitability

Profitability metrics for Parnax Lab Ltd in Q4FY26 show that the Profit Before Tax (PBT) was ₹3.00 crores, which is a decrease from ₹3.25 crores in Q3FY26, resulting in a QoQ decline of 7.7%. Compared to Q4FY25, where the PBT was ₹3.95 crores, there is a YoY reduction of 24.1%. The Profit After Tax (PAT) for Q4FY26 was ₹2.19 crores, down from ₹2.71 crores in the previous quarter, marking a QoQ decline of 19.2%. In comparison to the same period last year, the PAT was ₹2.93 crores, reflecting a YoY decrease of 25.3%. Earnings per Share (EPS) also declined, with Q4FY26 figures at ₹1.90 compared to ₹2.37 in Q3FY26 and ₹2.55 in Q4FY25, showing reductions of 19.8% QoQ and 25.5% YoY.

Operating Metrics

The total expenses for Parnax Lab Ltd in Q4FY26 amounted to ₹68.39 crores. This is an increase from ₹59.52 crores in Q3FY26, representing a QoQ growth of 14.9%. When compared to Q4FY25, which recorded expenses of ₹45.52 crores, there is a YoY increase of 50.2%. The tax expense for Q4FY26 was ₹0.81 crores, up from ₹0.53 crores in the previous quarter, indicating a QoQ increase of 52.8%. However, compared to the same period last year (Q4FY25) where the tax was ₹1.03 crores, there is a YoY decrease of 21.4%. These metrics illustrate the financial shifts in Parnax Lab Ltd's operational costs and tax liabilities over the given periods.